Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
SN

SNOAStock

Nasdaq Capital Market · Healthcare

$0.8318 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment SNOA's does — no target price to set, unlike a price alert.

Near limit Ratio screen, 2 of 7 decided standards passing. FTSE Shariah is within 3 points of its line. Even if it crossed, the majority verdict would stay Not compliant. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
2 of 7 pass our own screen — the standards disagree
Purification 100.00% *HTR non-permissible income <0.01%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 4 timeframes bullish · 76.5% aligned
VWAPPrice below VWAP ($0.99)
VolumeRelative volume 9.5× the 20-day average
Momentum10-day rate of change -26.9%

SNOA is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Institutional own.
6.5%
of shares
Momentum (10d)
-26.9%
rate of change
SMC grade
D · 37
76.5% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
<0.01%
Non-permissible income — HTR, from filings (2026-09-30)
D · 37
SMC grade — 76.5% timeframe alignment
-26.9%
Rate of change (10d)
6.5%
Institutional ownership

How the status reached this point

Non-compliant · status tracked since Nov 17, 2026

No change to SNOA’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 17, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $5.5M as of 2026-11-15.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 2 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 10.91% 30.00% Pass(19.1pp buffer)
Interest-bearing investments 83.54% 30.00% Fail(53.5pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Usmani Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 3.52% 33.00% Pass(29.5pp buffer)
Interest-bearing investments 26.95% 33.00% Pass(6.1pp buffer)
Non-liquid assets 52.11% at least 20.00% Pass(32.1pp above the floor)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI Fail 3 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 3.52% 33.33% Pass(29.8pp buffer)
Cash + interest-bearing securities 26.95% 33.33% Pass(6.4pp buffer)
Accounts receivable 47.89% 33.33% Fail(14.6pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
FTSE Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 0.33% 33.33% Pass(33.0pp buffer)
Cash + interest-bearing securities 26.95% 33.33% Pass(6.4pp buffer)
Accounts receivable 47.89% 50.00% Pass(2.1pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 4.27% 33.00% Pass(28.7pp buffer)
Cash + interest-bearing securities 32.72% 33.00% Pass(0.3pp buffer)
Accounts receivable 25.43% 33.00% Pass(7.6pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 4.96% 33.00% Pass(28.0pp buffer)
Cash + interest-bearing securities 37.94% 49.00% Pass(11.1pp buffer)
Accounts receivable 29.49% 49.00% Pass(19.5pp buffer)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)
MSCI M-Series Fail 2 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 4.96% 33.33% Pass(28.4pp buffer)
Cash + interest-bearing securities 37.94% 33.33% Fail(4.6pp over)
Accounts receivable 67.43% 49.00% Fail(18.4pp over)
Non-permissible income 0.00% 5.00% Pass(5.0pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Dow Jones Islamic Market (% of 24-mo avg market cap)cash and interest ratio 0.3pts
FTSE Shariah Global Equity Index Series (% of total assets)receivables ratio 2.1pts
AAOIFI Standard 21 (% of market cap)non permissible income ratio 5.0pts
AAOIFI Standard 21 (% of market cap)investments ratio 53.5pts
MSCI Islamic M-Series (% of 36-mo avg market cap)receivables ratio 18.4pts
MSCI Islamic Index (% of total assets)receivables ratio 14.6pts

The numbers the ratios are built from

Read from SNOA's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $19.5M 2026-09-30 Revenues
Interest-bearing debtShort and long-term borrowings $57.0K 2026-09-30 ShortTermBorrowings
Cash and interest-bearing securitiesCash, equivalents and marketable securities $4.6M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $17.1M 2026-09-30 Assets
Market capDenominator for AAOIFI $5.5M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $4.4M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $5.1M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2026-09-30 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2026-09-30. Screened 2026-11-15.

A newer filing exists: our EDGAR watch has seen one since this screen and it is queued for re-screening. The figures below are from the filings named, not the newer one.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$17.1M
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$57.0K
    ShortTermBorrowings · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$4.6M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · balance sheet as of 2026-09-30
  • Receivables$3.6M
    AccountsReceivableNetCurrent · balance sheet as of 2026-09-30
  • Revenue$19.5M
    Revenues · income statement as of 2026-09-30
  • Interest income (non-permissible)$0
    no interest-income tag reported in 3+ years (treated as $0) · income statement as of 2026-09-30
  • Market cap$5.5M
    Market-data quote at screen time, 2026-11-15 · not a filing figure, so no link

What changed, and when

Verdict history for SNOA. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for SNOA has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 2 pass and 5 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-15.

Within 3 points of the line

FTSE Shariah is within 3 points of its line. Even if it crossed, the majority verdict would stay Not compliant.

The ratios that move with the share price

AAOIFI's debt ratio (10.9% against a 30% line) would only fail if the market cap fell by 64%, to $2.0M.

AAOIFI's investments ratio is $4.6M cash and interest-bearing investments over a market cap of $5.5M (as of 2026-11-15), 83.5% against a 30% line.

It would pass if the market cap rose above $15.4M (+178%), about $3.04 a share against $1.09 implied by the screen's own figures.

AAOIFI would then pass; the majority verdict would stay Not compliant (3 of 7 decided standards passing).

At the screen's market cap, it would take $3.0M less cash and interest-bearing investments to clear the line.

AAOIFI would then pass, and the majority verdict would move from Not compliant to Compliant (4 of 7 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Drug Manufacturers - Specialty & Generic listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
GALDYGalderma Group AG - ADR $47.7B —
HLNHaleon plc - ADR $44.4B —
NBIXNeurocrine Biosciences, Inc. $15.9B —
RDYDr. Reddy`s Laboratories Ltd. - ADR $10.1B —
ALKSAlkermes plc $7.9B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding SNOA
InvestorFirmPositionWeightAs of
Peter Brown Renaissance Technologies $0M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

3.803.062.311.570.832025-11-182026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
0.75
S2
0.78
S1
0.81
PIVOT
0.84
R1
0.87
R2
0.90
R3
0.93

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
1.01 – 1.35
±14.57% from 1.18, made 2026-10-14 · resolves 2026-10-21
STRONG SELL
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsNEUTRAL
3 buy · 1 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)30.80NEUTRAL
Stochastic %K (14)10.54BUY
CCI (20)-256.33BUY
Williams %R (14)-89.46BUY
MACD (12,26,9)-0.03SELL
ROC (10)-23.41SELL
Momentum (10)-0.26SELL
EMA (10)1.01SELL
SMA (10)1.05SELL
EMA (20)1.07SELL
SMA (20)1.09SELL
EMA (30)1.10SELL
SMA (30)1.12SELL
EMA (50)1.15SELL
SMA (50)1.17SELL
EMA (100)1.27SELL
SMA (100)1.22SELL
EMA (200)1.75SELL
SMA (200)1.56SELL

About SNOA

Healthcare · Drug Manufacturers - Specialty & Generic

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

sonomapharma.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 43
🕐 1H RANGING 48
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-26.9%
Rate of change (10d)
9.5×
Volume vs its 20-day average
-0.07
MACD (no fresh cross)
$0.85
Volume POC (today)
$0.82 – $0.85
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.